Oncology Nurses Identify Crucial Unmet Needs in Patients With GU Cancers | Cancer Nursing Today
Patients with genitourinary (GU) cancers have high levels of unmet need when it comes to emotional support, intimacy, and informational support.
Related Articles
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
Key Points. The incidence of primary refractory disease has decreased with modern therapy, but it is a significant risk factor for shorter survival.Salvage auto
Sleep & Sleep Disorders | Insomnia,
Sleep information – Importance of sleep, sleep benefits, sleep stages, sleep hygiene, sleep depreciation, sleep problems/disorders, and sleep aids.
Pennsylvania Online Therapy & Counseling – Makin Wellness
Pennsylvania’s #1 online therapy & counseling centers. Click here for help with relationships and all other mental health needs.
A Wrap-up of Notable Updates, Breakthroughs in Sleep Medicine in 2024 | Docwire News
Dr. Anne Morse provides a run-down of the important trends, and therapeutic innovations to occur in sleep medicine this year.
The Uromigos Episode 376: Bladder Cancer 2024 Highlights | GU Oncology Now
Dr. Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer from 2024.
Donate to The Leukemia & Lymphoma Society
Make a difference today in a blood cancer patient’s life by supporting The Leukemia & Lymphoma Society https://givenow.lls.org/give/342076/#!/donation/checkout
Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow | Docwire News
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
NEST-1: Neoadjuvant Botensilimab, Balstilimab for pMMR/MSS CRC | Docwire News
Dr. Kasi showcases NEST-1, a look at adverse events and downstaging effects from neoadjuvant bot/bal in pMMR/MSS CRC.
Patient-Derived RCC Organoids Promising to Personalized Therapy, Understanding Treatment Resistance | GU Oncology Now
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
CARTITUDE-4 Analysis: Ciltacabtagene Autoleucel Shows Long-Term Benefits in Quality of Life | Cancer Nursing Today
An analysis of CARTITUDE-4 presented at ASH 2024 showed ciltacabtagene autoleucel has long-term benefits for quality of life in patients with multiple myeloma.